Interspecies allometric scaling.

Area of Science:

• Veterinary Pharmacology
• Wildlife and Zoo Animal Medicine
• Pharmacokinetics

Background:

• Limited approved pharmaceutical agents and pharmacokinetic data exist for exotic, wildlife, and zoo species.
• Veterinarians often extrapolate drug use from domestic animals or human medicine without scientific basis.
• Species-specific differences in drug absorption, metabolism, distribution, and excretion are poorly understood in nondomestic species.

Purpose of the Study:

• To highlight the critical need for pharmacokinetic data in exotic, wildlife, and zoo species.
• To underscore the challenges faced by veterinarians in selecting appropriate drugs and dosages for these animals.
• To emphasize the importance of species-specific research to inform drug therapy in nondomestic animals.

Main Methods:

• Review of existing scientific literature on drug use and pharmacokinetics in nondomestic species.
• Analysis of anatomical and physiological differences impacting drug absorption and metabolism across various species groups.
• Consideration of factors such as body size, digestive system variations, and temperature dependency in poikilothermic species.

Main Results:

• Fewer than 15 drugs are approved in the US for zoo and wildlife species, compared to nearly 300 for cattle.
• Significant pharmacokinetic variations exist due to anatomical differences (e.g., digestive systems) and physiological factors (e.g., temperature).
• Lack of data necessitates 'trial and error' approaches, which are often inappropriate given the value and conservation status of many zoo animals.

Conclusions:

• There is an urgent need for dedicated pharmacokinetic studies in exotic, wildlife, and zoo species.
• Developing species-specific drug guidelines is crucial for improving treatment efficacy and animal welfare.
• The 'One Medicine' approach requires a better understanding of interspecies pharmacokinetic variability to ensure safe and effective veterinary care.